United-Guardian (NASDAQ:UG – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.
Profitability
This table compares United-Guardian and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| United-Guardian | 22.01% | 22.24% | 19.12% |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Earnings & Valuation
This table compares United-Guardian and Aditxt”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| United-Guardian | $10.55 million | 3.10 | $2.11 million | $0.54 | 13.20 |
| Aditxt | $14,336.00 | 0.27 | -$41.71 million | ($100,788.35) | -0.00 |
United-Guardian has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
United-Guardian has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for United-Guardian and Aditxt, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| United-Guardian | 0 | 1 | 0 | 0 | 2.00 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Institutional and Insider Ownership
23.2% of United-Guardian shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 29.0% of United-Guardian shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
United-Guardian beats Aditxt on 11 of the 12 factors compared between the two stocks.
About United-Guardian
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Receive News & Ratings for United-Guardian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United-Guardian and related companies with MarketBeat.com's FREE daily email newsletter.
